JANSSEN-CILAG PTY LTD

Cytrill BV raised €85m in Series B funding, co-led by Johnson & Johnson Innovation, Forbion, and Novartis Venture Fund, to advance CIT-013, a monoclonal antibody targeting Neutrophil Extracellular Traps (NETs). CIT-013, which completed Phase I studies in RA patients, aims to clear existing NETs and inhibit new formation, with potential applications in various immune-mediated inflammatory diseases. New board members include Geert-Jan Mulder, Florian Muellershausen, and a JJDC representative.

Timmerman Report celebrates its 10th anniversary with events in Boston (Mar. 6) and Seattle (Mar. 13), featuring biotech leaders discussing future trends in biopharma.

New York start-up Metsera raises $215 million in Series B, bringing total funding to over $500 million in seven months, to accelerate development of its obesity drug pipeline, including MET-097i and MET-233i. Swiss biotech Alentis Therapeutics secures $181 million for claudin-1 targeting ADCs, while Trace Neuroscience raises $101 million for ALS treatment. TRex Bio completes $84 million Series B for TNFR2 agonist development.

Dyania Health, an AI-enabled healthcare data company, closed a $10 million Series A funding round led by HealthX, TechSquare, and Cleveland Clinic Ventures. The Synapsis AI platform automates medical data reading and analysis, aiming to streamline clinical research and improve healthcare quality. The funding will accelerate AI capabilities to address inefficiencies in clinical research and patient care.